Confidential settlements in securities-fraud opt-outs tied to Teva’s drug-pricing and governance misconduct
Plaintiff(s):
Institutional investors pursuing direct opt-out actions in parallel with the securities class action
Case type / claims:
Governance-related securities fraud and misleading disclosures concerning Teva’s drug-pricing practices and participation in an alleged generic-drug price-fixing conspiracy; claims asserted under U.S. and Israeli securities laws
Defendant(s):
Teva Pharmaceutical Industries Ltd. and senior executives
Jurisdiction:
U.S. District Court for the District of Connecticut
Year:
2023
Outcome:
- Achieved favorable confidential resolutions of multiple direct opt-out securities actions for institutional clients.
- Complemented ongoing antitrust enforcement actions by U.S. State Attorneys General, the U.S. DOJ, and private plaintiffs alleging price-fixing across the generic drug industry.
